atorvastatin has been researched along with Osteonecrosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alves, K; Alves, NM; Brito, GAC; de Sousa, VC; Girão, V; Goes, P; Leitão, R; Lopes, AP; Martins, CS; Sousa, FRN; Vasconcelos, RF; Viana, D | 1 |
| Pazianas, M | 1 |
| Belmont, HM; Lydon, E | 1 |
1 trial(s) available for atorvastatin and Osteonecrosis
| Article | Year |
|---|---|
Avascular necrosis prevention with lipitor in lupus erythematosus.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Osteonecrosis; Pyrroles | 2005 |
2 other study(ies) available for atorvastatin and Osteonecrosis
| Article | Year |
|---|---|
Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Topics: Animals; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Jaw; Osteonecrosis; Rats; Zoledronic Acid | 2022 |
Atorvastatin reduces zoledronic acid-induced osteonecrosis of the jaws of rats.
Topics: Animals; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Jaw; Osteonecrosis; Rats; Zoledronic Acid | 2022 |